Synlogic stock.

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...Second Quarter 2022 Financial Results. As of June 30, 2022, Synlogic had cash, cash equivalents and short-term investments of $106.8 million. Revenue for the three months ended June 30, 2022 and ...Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Synlogic (NASDAQ:SYBX) is undoubtedly a potential 10X investment, judging by its numbers alone.Shares of SYBX stock trade at only 53 cents per share, while its target stock price is $7.17.So, it ...Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are ...

Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis.About Synlogic. Synlogic ™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways.

Synlogic saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 90,800 shares, a decline of 41.7% from the previous total of 155,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment.

Oct 20, 2022 · Synlogic was spun out of MIT and uses technology developed by Drs. Tim Lu and Jim Collins. Synlogic was founded in 2014 and became a public company via a reverse merger in 2017. The first ... What is the target price for Synlogic (SYBX) stock? A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on Friday, August 11, 2023. The analyst firm set a price ...Dec 1, 2023 · Earnings Flash (SYBX) SYNLOGIC Posts Q3 Revenue $393,000. Nov. 09. MT. Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 09. CI. Synlogic, Inc. Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration. Nov. 07. CI. Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuriaCAMBRIDGE, Mass., March 20 ...

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study. December …

Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 ... Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in …Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November.Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug ...Find the latest Synlogic Inc (MINA.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.Fourth Quarter 2021 Financial Results. As of December 31, 2021, Synlogic had cash, cash equivalents, and marketable securities of $136.6 million. Revenue was $0.6 million for the three months ...Get the latest Synlogic, Inc. (SYBX) stock news and headlines to help you in your trading and investing decisions.Synlogic Stock Price, News & Analysis (NASDAQ:SYBX) $2.39 +0.30 (+14.35%) (As of 11/29/2023 ET) Compare Today's Range $2.00 $2.40 50-Day Range …

CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...Synlogic Inc SYBX Morningstar Rating Unlock Stock XNAS Rating as of Nov 17, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ...It’s a gamble. That said, these three penny stocks in the biotech and Pharma space are worth considering. EFTR eFFECTOR Therapeutics $0.54 SYBX Synlogic $0.53 ALZN Alzamend Neuro $0.53.

Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...

Business News - Latest Headlines on CNN Business - CNNSynlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic ...Nov 30, 2023 · Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. Synlogic trades on the NASDAQ stock market under the symbol SYBX. What is Synlogic stock price doing today? As of November 24, 2023, SYBX stock price declined to $2.00 with 12,590 million shares trading.Synlogic (SYBX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow. SA Transcripts Fri, Nov. 17, 2017 1 Comment. All earnings call transcripts on Synlogic, Inc. (SYBX) stock. Read ...Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the appointment of Antoine Awad as Head of Technical Operations, and the expansion of its manufacturing capabilities to produce clinical trial …

24.65%. Get the latest Synlogic Inc (SYBX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.- Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell, Ph.D., and Richard Shea. CAMBRIDGE, Mass. & AUSTIN, …Synlogic Inc (SYBX). Sector: HEALTH CARE. Industry: BIOTECHNOLOGY & LIFE SCIENCES. SIC: PHARMACEUTICAL ... Stock Lookup. Enter stock name: use * for wildcard.SYBX | Overview of Synlogic Inc stock by Investoreight. View stock price, financials, news, earnings, and performance of Synlogic Inc - Investoreight.Sep-22-21 11:32PM. Synlogic Announces Pricing of Public Offering of Common Stock. (PR Newswire) Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory …Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.Synlogic has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off last year's report dates. Learn more on SYBX's earnings history.Common stock and common stock equivalents Common stock 66,736,251 69,698,844 Common stock warrants (pre-funded) 2,548,117 2,548,117 Total common …Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Synlogic (SYBX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow. SA Transcripts Fri, Nov. 17, 2017 1 Comment. All earnings call transcripts on Synlogic, Inc. (SYBX) stock. Read ...$-12.72 Market Cap $18.29 M Shares Outstanding 9.19 M Public Float 4.54 M Yield SYBX is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short …

Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.If your Synlogic shares are registered in your own name, please contact our transfer agent, American Stock Transfer & Trust Company, LLC, and inform them of your request by calling them at 1-800-937-5449 or writing them at 6201 15th Avenue, Brooklyn, NY 11219.Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 4,025% from the current SYBX share price of $2.00. Instagram:https://instagram. best financial advisors in californiaconcentrix corpbudd stocktesla stock projections Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of Mirna holding approximately 32% of the outstanding Mirna common stock and certain officers, directors and stockholders of Synlogic holding approximately 84% of the Synlogic capital stock (giving effect to Synlogic’s recent Series C financing) have … zm stock forecastbest bank for cash out refinance If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets. tesla stock buy or sell Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...Company Overview. Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential …Synlogic ( SYBX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 9, 2023 for Q3 and the Actual Revenue was $393K, which beat the ...